Lv1
50 积分 2025-12-28 加入
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
29天前
已关闭
SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy
29天前
已完结
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
1个月前
已完结
Efficacy of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor
1个月前
已完结
Clinical outcomes and tumor immune microenvironment in SMARCA4-Deficient NSCLC: A Real-World retrospective study
1个月前
已完结
Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer
1个月前
已完结
Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies
1个月前
已完结
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics
1个月前
已完结
A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice
2个月前
已完结
皖公网安备34019202002308
